Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations.

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Corrigendum to “Simulation of peri-implant bone healing due to immediate loading in dental implant treatments” [J. Biomech. 46/5 (2013) 871–878] Hsuan-Yu.

The Survival Kit: Software to analyze survival data including possibly correlated random effects G. Mészáros, J. Sölkner, V. Ducrocq Computer Methods and.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306) D.P. Modest, I. Ricard,

Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one.

European Journal of Cancer

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase.

European Journal of Cancer

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Axel.

Rare cancers of the head and neck area in Europe

Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: A Taiwanese Gynecologic Oncology Group study Kung-Liahng.

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer Philippe O. Gannon, Laurent Lessard, Louis-Mathieu.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind.

Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without.

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

Volume 67, Issue 2, Pages (August 2017)

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic.

Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk Ana Lívia Silva Galbiatti, Lidia Maria Rebolho.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 16, Issue 2, Pages (August 2009)

The GAPs between hepatocellular carcinoma and RAS

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait,

Author gender in The Lancet journals

Lymphotoxins: New Targets for Hepatocellular Carcinoma

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection Adam.

Hepatitis B and C virus-related carcinogenesis

Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers.

Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis.

The place of downstaging for hepatocellular carcinoma

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

Volume 65, Issue 4, Pages (October 2016)

European Association for the Study of the Liver Journal of Hepatology

Volume 68, Issue 1, Pages (January 2018)

The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood D.G.M. McDonald, Y. Najam, M.B. Keegan, M. Whooley,

Targets for immunotherapy of liver cancer

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study Gyuri Kim, Suk-Yong Jang, Chung.

Analysis of admixture in Native American populations from Colombia

Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts Chiara Raggi, Pietro Invernizzi,

Why men are at higher risk for hepatocellular carcinoma?

Treatment response after radioembolisation in patients with hepatocellular carcinoma— An evaluation with dual energy computed-tomography Jens Altenbernd,

Volume 14, Issue 9, Pages (August 2013)

Genomic risk of hepatitis C-related hepatocellular carcinoma

Autophagy in the liver Journal of Hepatology

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Confessions of a journal junkie

European Urology is “Your” Journal

Hepatitis B and C virus-related carcinogenesis

Molecular prognostication of liver cancer: End of the beginning

Initial experience with irreversible electroporation of liver tumours

Evolution of liver transplantation for hepatocellular carcinoma

Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma

Increasing incidence of brain tumours in sparsely populated areas

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Volume 66, Issue 3, Pages (March 2017)

Hepatocellular Carcinoma

Volume 70, Issue 4, Pages (April 2019)

Liver Transplantation for Hepatocellular Carcinoma

New trials and results in systemic treatment of HCC

Genetics of hepatocellular carcinoma: The next generation

Volume 54, Issue 1, Pages (July 2008)

Partial hepatectomy vs

Reversion of disease manifestations after HCV eradication

Friedrich Foerster, Peter Robert Galle JHEP Reports

Presentation transcript:

Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience V.B. Weeda, M. Murawski, A.J. McCabe, R. Maibach, L. Brugières, D. Roebuck, M. Fabre, A. Zimmermann, J.B. Otte, M. Sullivan, G. Perilongo, M. Childs, P. Brock, J. Zsíros, J. Plaschkes, P. Czauderna, D.C. Aronson European Journal of Cancer Volume 49, Issue 12, Pages 2698-2704 (August 2013) DOI: 10.1016/j.ejca.2013.04.012 Copyright © 2013 Elsevier Ltd Terms and Conditions

Fig. 1 Kaplan–Meier estimate of event free survival (EFS) for fibrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional hepatocellular carcinoma (HCC) group. EFS FL-HCC versus HCC at 3 years follow-up was compared for proportions by z-test; p=0.30. European Journal of Cancer 2013 49, 2698-2704DOI: (10.1016/j.ejca.2013.04.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Fig. 2 Kaplan–Meier estimate of overall survival (OS) for fibrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional hepatocellular carcinoma (HCC) group. OS FL-HCC versus HCC at 3 years follow up was compared for proportions by z-test; p=0.24. European Journal of Cancer 2013 49, 2698-2704DOI: (10.1016/j.ejca.2013.04.012) Copyright © 2013 Elsevier Ltd Terms and Conditions